Original Research

Published on 24 Jan 2024

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)

in Pharmacology of Anti-Cancer Drugs

Yiwen Bao
Jiaju Chen
Luting Duan
Fujue Wang
Han Lai
Zeming Mo
Weiliang Zhu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1288362

2,054 views
1 citation

Systematic Review

Published on 24 Jan 2024

Sustained efficacy of chimeric antigen receptor T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis of individual data

in Pharmacology of Anti-Cancer Drugs

Jing Zhou
Zhenhao Wang
Hanyu Wang
Yang Cao
Gaoxiang Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1331844

1,074 views

Systematic Review

Published on 23 Jan 2024

A global bibliometric and visualized analysis of the links between the autophagy and acute myeloid leukemia

in Pharmacology of Anti-Cancer Drugs

Yao Gao
Zhenhui Wu
Yingfan Chen
Guangbin Shang
Yingjian Zeng
Yue Gao

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1291195

1,545 views
2 citations

Review

Published on 23 Jan 2024

GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs

in Pharmacology of Anti-Cancer Drugs

Qingzhi Ji
Huimin Zhu
Yuting Qin
Ruiya Zhang
Lei Wang
Erhao Zhang
Xiaorong Zhou
Run Meng

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1329636

2,430 views

Systematic Review

Published on 22 Jan 2024

The efficacy of bevacizumab combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials

in Pharmacology of Anti-Cancer Drugs

Guangsu Han
Chenlu Li
Ping Yi

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1293039

1,045 views

Review

Published on 19 Jan 2024

Ferroptosis in head and neck squamous cell carcinoma: from pathogenesis to treatment

in Pharmacology of Anti-Cancer Drugs

Jing Yang
Zhaowei Gu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1283465

1,679 views

Original Research

Published on 19 Jan 2024

The potential mechanism of Aidi injection against neuroblastoma—an investigation based on network pharmacology analysis

in Pharmacology of Anti-Cancer Drugs

Shuyang Dai
Yaoyao Gu
Yong Zhan
Jie Zhang
Lulu Xie
Yi Li
Yifei Lu
Ran Yang
Enqing Zhou
Deqian Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1310009

1,575 views

Original Research

Published on 18 Jan 2024

In vitro cytotoxicity of Withania somnifera (L.) roots and fruits on oral squamous cell carcinoma cell lines: a study supported by flow cytometry, spectral, and computational investigations

in Pharmacology of Anti-Cancer Drugs

Ahmed Abdullah Al Awadh
Hiroshi Sakagami
Shigeru Amano
Ahmed M. Sayed
Mohamed E. Abouelela
Abdulaziz Hassan Alhasaniah
Nayef Aldabaan
Mohamed S. Refaey
Reda A. Abdelhamid
Heba M. A. Khalil

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1325272

2,166 views
1 citation

Correction

Published on 17 Jan 2024

Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy

in Pharmacology of Anti-Cancer Drugs

Naveen Kumar Velayutham
Tamilanban Thamaraikani
Shadma Wahab
Mohammad Khalid
Gobinath Ramachawolran
Shahabe Saquib Abullais
Ling Shing Wong
Mahendran Sekar
Siew Hua Gan
Angel Jemima Ebenezer

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1343756

787 views

Original Research

Published on 16 Jan 2024

Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth

in Pharmacology of Anti-Cancer Drugs

Ke Wang
Pei-Yin Liao
Wei-Chun Chang
Cian-Ru Yang
Yu-Ting Su
Ping-Ching Wu
Yang-Chang Wu
Yao-Ching Hung
Najim Akhtar
Hsueh-Chou Lai

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1281067

1,381 views

Original Research

Published on 16 Jan 2024

Exposure–response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab

in Pharmacology of Anti-Cancer Drugs

Suemin Park
Jin Ah Jung
Sungil Ju
Hyeong-Seok Lim

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1288308

1,256 views

Review

Published on 16 Jan 2024

Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review

in Pharmacology of Anti-Cancer Drugs

Angelika Buczyńska
Maria Kościuszko
Adam Jacek Krętowski
Anna Popławska-Kita

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1323083

1,745 views

Original Research

Published on 16 Jan 2024

A glycosylation-related gene signature predicts prognosis, immune microenvironment infiltration, and drug sensitivity in glioma

in Pharmacology of Anti-Cancer Drugs

Yanbo Yang
Haiying Teng
Yulian Zhang
Fei Wang
Liyan Tang
Chuanpeng Zhang
Ziyi Hu
Yuxuan Chen
Yi Ge
Zhong Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1259051

2,287 views
1 citation

Systematic Review

Published on 15 Jan 2024

Bibliometric analysis of photodynamic therapy and immune response from 1989–2023

in Pharmacology of Anti-Cancer Drugs

Wanting Fan
Jianming Tang
Su Tang
Zhengshen Lin
Mohan Li
Zheng Zhang
Donglei Wu

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1299253

1,225 views

Original Research

Published on 15 Jan 2024

OTUD3 suppresses the mTORC1 signaling by deubiquitinating KPTN

in Pharmacology of Anti-Cancer Drugs

Jiatao Li
Dan Yang
Yan Lin
Wei Xu
Shi-min Zhao
Chenji Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1337732

1,160 views

Systematic Review

Published on 15 Jan 2024

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials

in Pharmacology of Anti-Cancer Drugs

Dongqing Pu
Yue Wu
Debo Xu
Guangxi Shi
Hanhan Chen
Dandan Feng
Mengdi Zhang
Jingwei Li

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1269922

2,531 views
1 citation

Navigation group

Articles

Comparing the difference of adverse events with HER2 inhibitors: a study of the FDA adverse event reporting system (FAERS)

Sustained efficacy of chimeric antigen receptor T-cell therapy in central nervous system lymphoma: a systematic review and meta-analysis of individual data

A global bibliometric and visualized analysis of the links between the autophagy and acute myeloid leukemia

GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs

The efficacy of bevacizumab combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials

Ferroptosis in head and neck squamous cell carcinoma: from pathogenesis to treatment

The potential mechanism of Aidi injection against neuroblastoma—an investigation based on network pharmacology analysis

In vitro cytotoxicity of Withania somnifera (L.) roots and fruits on oral squamous cell carcinoma cell lines: a study supported by flow cytometry, spectral, and computational investigations

Corrigendum: Stylopine: a potential natural metabolite to block vascular endothelial growth factor receptor 2 (VEGFR2) in osteosarcoma therapy

Linoleate-pazopanib conjugation as active pharmacological ingredient to abolish hepatocellular carcinoma growth

Exposure–response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab

Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review

A glycosylation-related gene signature predicts prognosis, immune microenvironment infiltration, and drug sensitivity in glioma

Bibliometric analysis of photodynamic therapy and immune response from 1989–2023

OTUD3 suppresses the mTORC1 signaling by deubiquitinating KPTN

The adverse events of CDK4/6 inhibitors for HR+/ HER2- breast cancer: an umbrella review of meta-analyses of randomized controlled trials